Trial Profile

Safety and Efficacy of Mitapivat Sulfate in Adult Patients With Erythrocyte Membranopathies

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitapivat (Primary)
Indications Blood dyscrasias; Congenital haemolytic anaemia; Congenital-dyserythropoietic-anemia
Focus Adverse reactions
Acronyms SATISFY
Sponsors Agios Pharmaceuticals

Most Recent Events

10 Dec 2024 Results ( As of July 2024, n=24) reporting data from all patients who completed the 8-week dose-escalation period, presented at the 66th American Society of Hematology Annual Meeting and Exposition
19 Dec 2023 Planned initiation date changed from 15 Sep 2023 to 21 Dec 2023.
11 Jul 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com